Market Place
Sourcing Support
Foghorn Presents Data on FHD-909 Degraders at AACR 2026
21 Apr 2026 //
GLOBENEWSWIRE
Foghorn Therapeutics Presents FHD-909 Data at 2026 AACR
09 Apr 2026 //
GLOBENEWSWIRE
Foghorn Therapeutics Shares 2025-26 Financial and Strategic Plans
11 Mar 2026 //
GLOBENEWSWIRE
Foghorn Therapeutics To Join Two Investor Conferences
24 Feb 2026 //
GLOBENEWSWIRE
Yatiri Bio Predicts AML Drug Response With Foghorn`s FHD-286
10 Feb 2026 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate in the Guggenheim Summit
03 Feb 2026 //
GLOBENEWSWIRE
Foghorn Therapeutics To Join 8Th Evercore Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Updates Q3 2025 Financials & Corporate
05 Nov 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Updates for Selective ARID1B
30 Oct 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Advances ARID1B Degrader At TPD Summit
16 Oct 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics to Present at Three Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Updates on Q2 2025 Financials and Corporate
05 Aug 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics to Join Four Investor Conferences
22 May 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics` Q1 2025 Financial and Corporate Update
14 May 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics to Join Citizens Life Sciences Conference
05 May 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Appoints Neil Gallagher, Stuart Duty to Board
01 May 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics presents new data on FHD-909 & pipeline
28 Apr 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics to Host Investor Event on Pipeline Update
15 Apr 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Reveals Preclinical Data at 2025 AACR Meeting
25 Mar 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics Financial Update for 2024 and 2025
06 Mar 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics to Join Two Investor Conferences
25 Feb 2025 //
GLOBENEWSWIRE
Foghorn Highlights Progress And 2025 Strategic Objectives
13 Jan 2025 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate in 3 Upcoming Investor Conf
12 Nov 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Q3 2024 Financial Update
04 Nov 2024 //
GLOBENEWSWIRE
Foghorn Doses First Patient With FHD-909 In SMARCA4 Solid Tumors
10 Oct 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate in the BMO Oncology Summit
01 Oct 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Appoints Anna Rivkin, Ph.D., as Chief Business Officer
03 Sep 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics To Participate In Two Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Foghorn to Present Preclinical Data from CBP and EP300 Protein Degrader Programs
10 Apr 2023 //
GLOBENEWSWIRE
